NeuroPace (NASDAQ:NPCE) stock drops as the company's NAUTILUS study for RNS System misses the primary endpoint for the overall trial
https://seekingalpha.com/news/4452536-neuropace-stock-falls-trial-for-rns-system-fails
NeuroPace (NASDAQ:NPCE) stock drops as the company's NAUTILUS study for RNS System misses the primary endpoint for the overall trial
https://seekingalpha.com/news/4452536-neuropace-stock-falls-trial-for-rns-system-fails
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.